Premium
Do inherited hypercoagulable states play a role in thrombotic events affecting kidney/pancreas transplant recipients?
Author(s) -
Adrogué Horacio E.,
Matas Arthur J.,
McGlen R.C.,
Key Nigel S.,
Gruessner Angelika,
Gruessner Rainer W.,
Humar Abhinav,
Sutherland David E.R.,
Kandaswamy Raja
Publication year - 2007
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2006.00574.x
Subject(s) - medicine , pancreas , thrombosis , pancreas transplantation , population , transplantation , gastroenterology , factor v leiden , kidney transplantation , venous thrombosis , environmental health
Background: Pancreas graft thrombosis remains the leading non‐immunologic cause of graft loss after pancreas transplantation. We studied the role of hypercoagulable states (HCS) in pancreas graft thrombosis (pthx). Methods: Between January 1, 1994, and January 1, 2003, 131 pancreas transplant recipients experienced a pthx (n = 67) or other thrombotic events. Fifty‐six recipients consented to have their blood drawn and tested for the HCS. These results were compared with a control group of pancreas transplant recipients who did not experience a thrombotic event. Fisher's exact test was used to compare the groups. Results: We found 18% of the recipients with pancreas thrombosis to have a HCS. Factor V Leiden (FVL) was found in 15% vs. 4% in the control group (p = ns) vs. 3–5% in the general white population. We found 3% of the pancreas thrombosis patients to have a prothrombin gene mutation (PGM) vs. 0% in the control group (p = ns) vs. 1–2% in the general white population. Conclusions: Of pancreas transplant recipients with thrombosis, 18% had one or more of the most common factors associated with a HCS (FVL or PGM). This can be compared with 4% in a control group and 4–7% in the general white population, respectively. Although the differences are not statistically significant due to small numbers, we feel that the findings may be clinically relevant. While this is only a pilot study, it may be reasonable to screen select pancreas transplant candidates for HCS, especially FVL and PGM, until more data become available.